2024 World Conference on Lung Cancer (WCLC) - Posters-P1.12A.13 When Targeted Therapy Targets the Heart: Osimertinib-related Cardiotoxicity in EGFR Mutated Non-Small Cell Lung Cancer

P1.12A.13 When Targeted Therapy Targets the Heart: Osimertinib-related Cardiotoxicity in EGFR Mutated Non-Small Cell Lung Cancer

Back to course

Pdf Summary

The retrospective analysis explores the use of cardiac imaging in patients with EGFR-positive non-small cell lung cancer (NSCLC) taking Osimertinib, especially concerning the risk of heart failure (HF). While Osimertinib is effective for certain EGFR mutations in lung cancer, it poses a risk for cardiac-related adverse events, including HF. The study, conducted within Kaiser Permanente Northern California, evaluated changes in ejection fraction (EF) measured by transthoracic echocardiogram (TTE) or multigated acquisition scan (MUGA) from one year before to one year after treatment discontinuation. <br /><br />Results showed a rare incidence of Osimertinib-induced HF, with only 10 hospitalization or emergency visits noted, translating to an incidence rate of 0.006 cases per person-year. Of these events, the majority (6 cases) involved patients who experienced a reduction in EF. The data indicated that routine cardiac monitoring had limited efficacy in preventing HF-related hospital visits, suggesting that regular EF monitoring might not be necessary for every patient on Osimertinib. Instead, it recommends focusing on high-risk patients, particularly those with preexisting cardiac conditions, for targeted EF monitoring.<br /><br />The study concludes that a reassessment of cardiac screening approaches is needed. This includes implementing more specific risk stratification and targeted monitoring to optimize healthcare resources and better manage costs. Future research should explore the implications of these findings to improve clinical practices and patient outcomes, potentially reshaping current protocols for EF monitoring in the context of Osimertinib treatment.

Asset Subtitle

Francisco Martinez

Meta Tag

Speaker Francisco Martinez

Topic Metastatic NSCLC – Targeted Therapy

Keywords

cardiac imaging

EGFR-positive NSCLC

Osimertinib

heart failure risk

ejection fraction

transthoracic echocardiogram

multigated acquisition scan

cardiac monitoring

risk stratification

healthcare resources